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Clinical Findings Form
• Timeline – In addition to 
generating if conditions 
occur, IMM v4.0 
generates when 
conditions occur.
• Partial Treatment – IMM 
v4.0 gives partial credit 
for partial treatment in 
generating the outcomes 
of a condition
• Alternative Drug – If a 
primary drug required for 
treatment is not available, 
IMM v4.0 searches for 
medically appropriate 
substitutes.
V&V Scope
New capabilities were examined in a comparative, 
stepwise approach as follows:
• comparison of the current operational IMM v3 with 
the enhanced functionality of timeline (IMM 4.T)
• comparison of IMM 4.T with the enhanced 
functionalities of timeline and partial treatment 
capability (IMM 4.TPT)
• comparison of IMM 4.TPT with the enhanced 
functionalities of timeline, partial treatment and 
alternative medication capability (IMM 4.0)
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Verification Objectives
Confirm that the IMM version undergoing evaluation 
functioned correctly and that this IMM version performed 
appropriately when compared to the previous IMM 
version:
• Events are distributed as specified
o Incidence rate and proportion
o Event timing
o Best and worst case scenarios
o Evacuation (EVAC) and loss of crew life (LOCL) 
assignments
• Quality-adjusted mission time lost is being calculated 
correctly 
• Resources are utilized and depleted correctly 
5
Validation Objectives
IMM primary outputs underwent quantitative evaluation and/ 
or face validation to confirm that the IMM version undergoing 
evaluation functioned correctly:
o Total medical events (TME)
o Crew health index (CHI)
o EVAC
o LOCL
o Resource utilization
• Quantitative: statistical significance assessed using 95% CI 
to test differences between compared outcomes
• Face validation: assessment of the model and/or its 
behavior by SMEs to determine whether the model outputs 
are reasonable 
o understanding directions and magnitudes of differences of the 
model and the RWS
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Validation Objectives 
(Hypothesized Qualitative Trends for Primary Outputs)
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Enhanced Functionality TME CHI EVAC LOCL Resource Utilization 
 Expected effect on IMM 4.T outputs compared to IMM V3 
Timeline (IMM 4.T) ↓ ↑ ↓ ↓ ↓ 
 Expected effect on IMM 4.TPT outputs compared to IMM 4.T 
Partial Treatment  
(IMM 4.TPT) 
↑ ↑ ↓ ↓ ↑ 
 Expected effect on IMM 4.0 outputs compared to IMM 4.TPT 
Alternate Medications 
(IMM 4.0) 
↑ ↑ ↓ ↓ ↑ 
 
Qualitative trend directions of the primary IMM outputs were 
hypothesized for mission scenario comparison of each successive 
implementation of new IMM capability. 
IMM version performed as hypothesized when compared with 
each successive implementation of new IMM capability
Methods
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Table 1: Design Reference Mission Characteristics 
Mission Duration 
Number of 2-person 
EVAs* 
Total 
EVAs 
EVA Schedule 
Lunar 
Sortie 
14 (days) 8 16 
every day from day 3 to day 
10 
ISS6 180 (days) 6 12 day 25, 50, 75, 100, 125, 150 
Mars 2.5 (years) 231 462 
every second day starting 
from day 180 
*Only two crew members are EVA eligible, 1 male, 1female (see Table 2 below) 
Table 2: Crew Characteristics 
 
Sex CAC EVA* Crowns Contacts Abdominal Surgery History 
Crew 1 M Yes No Yes No No 
Crew 2 M No Yes No No No 
Crew 3 M No No No Yes No 
Crew 4 M No No No Yes Yes 
Crew 5 F No Yes Yes No No 
Crew 6 F No No No Yes No 
*EVA schedule described in Table 1 
M- male(s); F- female(s); CAC- coronary artery calcium 
•Crew characteristics
o Six- 4 males, 2 females
o Diverse physiological traits representative of astronaut 
corps
Results: TME 
(ISS6 DRM -MedCap Scenario)
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Total Medical Events- ISS6
Results: CHI 
(ISS6 DRM -MedCap Scenario)
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Crew Health Index- ISS6
Results: EVAC and LOCL 
(ISS6 DRM -MedCap Scenario)
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Results Summary
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Enhanced Functionality TME CHI EVAC LOCL Resource Utilization 
  IMM 4.T outputs compared to IMM V3 
Timeline (IMM 4.T) ↓ ↑ ↓ ↓ ↓ 
V3 106.41 90.36 0.1724 0.0051 739.29 
4.T 105.49 93.96 0.1418 0.0054 720.89 
 IMM 4.TPT outputs compared to IMM 4.T 
Partial Treatment (IMM 4.TPT) ↑ ↑ ↓ ↓ ↑ 
4.T 105.49 93.96 0.1418 0.0054 720.89 
4.TPT 105.97 94.87 0.0594 0.0043 724.09 
  IMM 4.0 outputs compared to IMM 4.TPT 
Alternate Medications (IMM 4.0) ↑ ↑ ↓ ↓ ↑ 
4.TPT 105.97 94.87 0.0594 0.0043 724.09 
4.0 106.02 94.92 0.0550 0.0042 723.41 
 
Summary
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• IMM 4.0 functionalities of timeline, partial treatment, and alternative 
treatments were added to IMM v3 to provide a closer approximation of 
the baselined real world system (i.e. the International Space Station). 
• V&V of these enhanced functionalities indicates that the IMM 4.0 
version is functioning correctly and performs as hypothesized based 
on meeting the proposed verification and validation objectives 
• Analysis confirmed: 
o medical events are distributed as specified by the IMM 
o quality-adjusted mission time lost is being calculated correctly
o resources are utilized and depleted correctly 
o total medical events, crew health index, probability of evacuation, 
and probability of loss of crew life were as hypothesized 
• Although original resource utilization hypotheses were not tested; 
subject matter expertise was used to evaluate the resources required-
with this consideration, no unacceptable findings were identified.
National Aeronautics and Space AdministrationNational Aeronautics and Sp ce Administration
INTEGRATED MEDICAL MODEL (IMM) 4.0 
VERIFICATION AND VALIDATION (V&V) 
TESTING
Thank you!
National Aeronautics and Space AdministrationNational Aeronautics and Sp ce Administration
INTEGRATED MEDICAL MODEL (IMM) 4.0 
VERIFICATION AND VALIDATION (V&V) 
TESTING
Back up Slides
16
• Verification: “…computational model 
accurately represents the underlying 
mathematical model…”
• Validation: “…determining the degree to 
which a model … is an accurate 
representation of the real world…”
• Credibility: “the quality to elicit belief or 
trust…”
Verification and Validation - DefinitionVV&C – Defining Terms for M&S
NASA-STD-7009, “Standard for Models and Simulations”, 2013.
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IMM Project VV&C History
• Medical Events
• Crew Impairment
• Loss of Crew Life
• Evacuation
• Resources Consumed
Probabilistic Risk Analysis / Monte Carlo Simulation
IMM
iMED Database
Resource
Optimization!
Scenario Definition (DRM)
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Methods: Crew Characteristics
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Table 1: Design Reference Mission Characteristics 
Mission Duration 
Number of 2-person 
EVAs* 
Total 
EVAs 
EVA Schedule 
Lunar 
Sortie 
14 (days) 8 16 
every day from day 3 to day 
10 
ISS6 180 (days) 6 12 day 25, 50, 75, 100, 125, 150 
Mars 2.5 (years) 231 462 
every second day starting 
from day 180 
*Only two crew members are EVA eligible, 1 male, 1female (see Table 2 below) 
Table 2: Crew Characteristics 
 
Sex CAC EVA* Crowns Contacts Abdominal Surgery History 
Crew 1 M Yes No Yes No No 
Crew 2 M No Yes No No No 
Crew 3 M No No No Yes No 
Crew 4 M No No No Yes Yes 
Crew 5 F No Yes Yes No No 
Crew 6 F No No No Yes No 
*EVA schedule described in Table 1 
M- male(s); F- female(s); CAC- coronary artery calcium 
NASA-Standard-7009 (July 2008)
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